title: Cytomegalovirus Treatment in Pediatric Hematopoietic Stem Cell Transplant Patients.
abstract: Cytomegalovirus (CMV) is a frequent complication of hematopoietic stem cell transplant in pediatric patients, with significant morbidity and mortality. Antiviral drugs are used as prophylactic, preemptive or therapeutic medicines; however, no uniform guidelines exist for the best strategy to prevent CMV disease. Resistance to standard antiviral therapies can lead to further difficulty in managing CMV disease. Studies for investigational therapies are underway and could provide options for treatment of resistant CMV, while limiting toxicities associated with currently used antiviral therapies.
authors.affiliation: *Department of Pharmacy, Norton Children's Hospital ‡Pediatric Cancer and Blood Disorders, University of Louisville, Louisville, KY †Department of Pharmacy, Children's Hospital Colorado, Aurora, CO.
authors.forename: Bethany A
authors.initials: BA
authors.lastname: Wattles
authors.forename: Abby J
authors.initials: AJ
authors.lastname: Kim
authors.forename: Alexandra C
authors.initials: AC
authors.lastname: Cheerva
authors.forename: Kenneth G
authors.initials: KG
authors.lastname: Lucas
authors.forename: Joshua J
authors.initials: JJ
authors.lastname: Elder
mesh_terms: D000293:Adolescent; D000998:Antiviral Agents / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003586:Cytomegalovirus Infections / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000150:complications / Q000628:therapy
chemical_list: D000998:Antiviral Agents